Home > Press > Zyvex Continues to Exceed Revenue Expectations
Long-term approach to nanotechnology commercialization is paying off
Zyvex Continues to Exceed Revenue Expectations
Richardson, TX | July 12, 2005
Zyvex today announced financial results for its fiscal 2005 second quarter. The Texas Company continues to exceed expectations with total revenue for the second quarter of $3.1 million — a 10 percent increase over plan and a 70 percent increase over the same period in 2004. For the first six months of 2005, revenue totaled $5.1 million — a 6 percent increase over plan and a 92 percent increase over the first six months of 2004. International sales accounted for 12 percent of the first six months revenue.
“Our long-term approach to nanotechnology commercialization is paying off,” stated Zyvex CFO Timothy M. Gilmore. “We recorded our second largest quarter in Zyvex’s history.”
“The reasons for our success are simple — we have a well thought-out plan and we execute to that plan daily,” said Zyvex President Thomas A. Cellucci, PhD., MBA. “Our team is comprised of talented and dedicated professionals who are totally focused on providing real-world nanotechnology solutions — today. At the same time, we’re developing new products based on systematic market analysis. We expect to meet or beat our plan for the remainder of the year and generate a substantial order backlog going into 2006.”
Founded in 1997, Zyvex reported its first revenue in 2001, grossing $150,000. Company revenue grew to $1.2 million in 2002, $4.3 million in 2003, and $8.6 million in 2004. Gilmore anticipates that the company will exceed $10 million in revenue during 2005, achieve cash-flow break-even by Q1 2006, and become bottom-line profitable by the end of 2006.
Zyvex recently won an “R&D 100” award for its NanoSolve® materials. The R&D 100 Award provides a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year.
Zyvex Corporation, based in Richardson, Texas, is the first molecular nanotechnology company. Zyvex’s vision is to be the leading worldwide supplier of tools, products, and services that enable adaptable, affordable, and molecularly precise manufacturing. Zyvex commercializes nanotechnology to address real-world applications with high growth potential. Zyvex carries its scientific breakthroughs into key commercial applications in the area of materials, tools, and structures.
For more information, please visit www.zyvex.com
Timothy M. Gilmore
Chief Financial Officer
Director of Corporate Communications
Copyright © Zyvex
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014
Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014
Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014
Innovative strategy to facilitate organ repair April 18th, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014